Section 5: Patient Safety and Quality Assurance

5PSQ-183

CONCOMITANT USE OF ACETYLCHOLINESTERASE INHIBITORS AND DRUGS WITH ANTICHOLINERGIC PROPERTIES AT ADMISSION BY EMERGENCY DEPARTMENT

5PSQ-182

ANTICHOLINERGIC BURDEN IN PATIENTS ADMITTED TO A PSYCHIATRIC HOSPITAL

5PSQ-181

IS INSTANT ALWAYS BETTER? PHARMACOKINETICS OF TABLET VERSUS GRANULATE FORMULATION OF PARACETAMOL IN FRAIL OLDER ADULTS

5PSQ-180

IMPACT OF SEDATIVE DRUGS ON VITAL SIGNS DURING PROCEDURAL SEDATION AND ANAESTHESIA: A RETROSPECTIVE COHORT ANALYSIS

5PSQ-179

REASON FOR DISCONTINUATION OF BIOLOGICAL DRUG TREATMENT IN RHEUMATOID ARTHRITIS

5PSQ-178

HEPATOTOXICITY ASSOCIATED WITH ACUTE TOCILIZUMAB TREATMENT IN PATIENTS WITH SARS-CoV-2 INFECTION

5PSQ-177

CARDIOVASCULAR RISK AND ALTERED LIPID PROFILE ASSOCIATED WITH TREATMENT WITH THE KINASE-JAK INHIBITORS, TOFACITINIB AND BARICITINIB

5PSQ-176

DISCONTINUATION OF ETANERCEPT DUE TO ADVERSE EVENTS IN PATIENTS WITH RHEUMATIC DISEASES

5PSQ-175

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 MUTATIONS ON T REG AND ABATACEPT: A PAEDIATRIC CASE REPORT

5PSQ-174

EFFECTIVENESS AND SAFETY OF ABATACEPT THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS AFTER PREVIOUS FAILURE WITH TNFi TREATMENT

5PSQ-173

PERSISTENCE OF ABATACEPT TREATMENT IN RHEUMATOID ARTHRITIS PATIENTS

5PSQ-172

EXPERIENCE WITH TOCILIZUMAB IN SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) INFECTION

5PSQ-171

TOCILIZUMAB IN PATIENTS WITH COVID19: RESULTS IN CLINICAL PRACTICE

5PSQ-170

PEMBROLIZUMAB IN NON-SMALL CELL LUNG CANCER: ANALYSIS IN REAL LIFE OF TOXICITY AND EFFECTIVENESS

5PSQ-169

SAFETY AND SEVERE NEUTROPENIA IN PATIENTS TREATED WITH PALBOCICLIB AND RIBOCICLIB IN REAL WORLD CLINICAL PRACTICE

Pages